June 12, 2024

Dr. Reddys-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.-Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.-Sales of the product for the past 12 months ended March 2024 were $51.8 million

by

Dr. Reddys

-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.

-Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys

-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.

-Sales of the product for the past 12 months ended March 2024 were $51.8 million

Please follow and like us:
fb-share-icon
Tweet
Pin Share

Related posts:

No related posts.

Tags:

Comments are closed.

You may also like

May 27, 2024
by

Kotak Inst Eqt on SUN TV* Buy, TP Rs 740 Ad revenue declined 2.5% yoy in 4Q, weak on both absolute & relative basis. Soft topline & higher costs led to a 14.5% yoy decline in core biz EBITDA Stock trading at 7X June 2026E core TV biz earnings*GOLDMAN SACHS on RIL* Buy, TP Rs 3420 RIL’s current discount to NAV of 19% is its widest since Jan 2021, with recent widening in discount potentially driven by a decline in Singapore refining margins & slight earnings miss in 4Q Believe multiple +ve catalysts ahead could drive share O-P StockMarket #Investment #FinancialNews #NIFTY Kotak Inst Eqt on SUN TV* Buy, TP Rs 740 Ad revenue declined 2.5% yoy in 4Q, weak on both absolute & relative basis. Soft topline & higher costs led to a 14.5% yoy decline in core biz EBITDA Stock trading at 7X June 2026E core TV biz earnings*GOLDMAN SACHS on RIL* Buy, TP Rs 3420 RIL’s current discount to NAV of 19% is its widest since Jan 2021, with recent widening in discount potentially driven by a decline in Singapore refining margins & slight earnings miss in 4Q Believe multiple +ve catalysts ahead could drive share O-P StockMarket #Investment #FinancialNews #NIFTY

Kotak Inst Eqt on SUN TV*Buy, TP Rs 740Ad revenue declined 2.5% yoy in 4Q, weak on both absolute &...